124 related articles for article (PubMed ID: 8589241)
1. A mixture model with detection limits for regression analyses of antibody response to vaccine.
Moulton LH; Halsey NA
Biometrics; 1995 Dec; 51(4):1570-8. PubMed ID: 8589241
[TBL] [Abstract][Full Text] [Related]
2. Asymmetric regression models with limited responses with an application to antibody response to vaccine.
Martínez-Flórez G; Bolfarine H; Gómez HW
Biom J; 2013 Mar; 55(2):156-72. PubMed ID: 23281068
[TBL] [Abstract][Full Text] [Related]
3. [A study on the level of antibody against measles through maternal-fetal transfer and the immuno-response to measles vaccine among 4 to 7 month olds].
Liu BY; Feng ZX; Xu AQ
Zhonghua Liu Xing Bing Xue Za Zhi; 1995 Oct; 16(5):263-5. PubMed ID: 8706090
[TBL] [Abstract][Full Text] [Related]
4. Measles vaccination in the presence of maternal antibodies primes for a balanced humoral and cellular response to revaccination.
Bertley FM; Ibrahim SA; Libman M; Ward BJ
Vaccine; 2004 Dec; 23(4):444-9. PubMed ID: 15530692
[TBL] [Abstract][Full Text] [Related]
5. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns.
Leuridan E; Van Damme P
Vaccine; 2007 Aug; 25(34):6296-304. PubMed ID: 17629601
[TBL] [Abstract][Full Text] [Related]
6. Girls may have lower levels of maternal measles antibodies and higher risk of subclinical measles infection before the age of measles vaccination.
Martins C; Bale C; Garly ML; Rodrigues A; Lisse IM; Andersen A; Eriksson M; Benn CS; Whittle H; Aaby P
Vaccine; 2009 Aug; 27(38):5220-5. PubMed ID: 19596409
[TBL] [Abstract][Full Text] [Related]
7. Designs for phase II trials allowing for a trade-off between response and toxicity.
Conaway MR; Petroni GR
Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459
[TBL] [Abstract][Full Text] [Related]
8. Immune response to measles vaccine in 6 month old infants in Papua New Guinea.
Kurubi J; Vince J; Ripa P; Tefuarani N; Riddell M; Duke T
Trop Med Int Health; 2009 Feb; 14(2):167-73. PubMed ID: 19171008
[TBL] [Abstract][Full Text] [Related]
9. Field trial to evaluate the immunogenicity of pseudorabies virus vaccines with deletions for glycoproteins G and E.
Firkins LD; Weigel RM; Biehl LG; Hahn EC
Am J Vet Res; 1997 Sep; 58(9):976-84. PubMed ID: 9285001
[TBL] [Abstract][Full Text] [Related]
10. Gender differences in the reactogenicity of measles-mumps-rubella vaccine.
Shohat T; Green MS; Nakar O; Ballin A; Duvdevani P; Cohen A; Shohat M
Isr Med Assoc J; 2000 Mar; 2(3):192-5. PubMed ID: 10774264
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children.
Wong-Chew RM; Islas-Romero R; García-García Mde L; Beeler JA; Audet S; Santos-Preciado JI; Gans H; Lew-Yasukawa L; Maldonado YA; Arvin AM; Valdespino-Gómez JL
Vaccine; 2006 Jan; 24(5):683-90. PubMed ID: 16154241
[TBL] [Abstract][Full Text] [Related]
12. Maternal antibody inhibits both cellular and humoral immunity in response to measles vaccination at birth.
Premenko-Lanier M; Hodge G; Rota P; Tamin A; Bellini W; McChesney M
Virology; 2006 Jul; 350(2):429-32. PubMed ID: 16569419
[TBL] [Abstract][Full Text] [Related]
13. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
14. A latent-class mixture model for incomplete longitudinal Gaussian data.
Beunckens C; Molenberghs G; Verbeke G; Mallinckrodt C
Biometrics; 2008 Mar; 64(1):96-105. PubMed ID: 17608789
[TBL] [Abstract][Full Text] [Related]
15. Bayesian variable selection method for censored survival data.
Faraggi D; Simon R
Biometrics; 1998 Dec; 54(4):1475-85. PubMed ID: 9883546
[TBL] [Abstract][Full Text] [Related]
16. Estimation of the time-dependent vaccine efficacy from a measles epidemic.
Eichner M; Diebner HH; Schubert C; Kreth HW; Dietz K
Stat Med; 2002 Aug; 21(16):2355-68. PubMed ID: 12210620
[TBL] [Abstract][Full Text] [Related]
17. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
Yin G; Li Y; Ji Y
Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
[TBL] [Abstract][Full Text] [Related]
18. Rural Kenya: measles during pregnancy and early infancy.
Arya SC; Agarwal N
J Infect Dis; 2006 Jan; 193(1):165-6; author reply 166-7. PubMed ID: 16323147
[No Abstract] [Full Text] [Related]
19. [Measles and mumps antibody concentrations in newborns and their mothers--follow up first year of life].
Hohendahl J; Peters N; Hüttermann U; Rieger C
Klin Padiatr; 2006; 218(4):213-20. PubMed ID: 16819702
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity assays and surrogate markers to predict vaccine efficacy.
Käyhty H
Dev Biol Stand; 1998; 95():175-80. PubMed ID: 9855429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
